Document is current
Any future updates will be listed below
-
Authors
Polymeris, Alexandros A. https://orcid.org/0000-0002-9475-2208
Lioutas, Vasileios-Arsenios
Marchina, Sarah
Seiffge, David J.
Roh, David J.
Poyraz, Fernanda Carvalho
Selim, Magdy H.
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02175225 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of Deferoxamine on Outcome According to Baseline Hematoma Volume: A Post Hoc Analysis of the i-DEF Trial
https://doi.org/10.1161/strokeaha.121.035421
Brain iron overload following intracranial haemorrhage
https://doi.org/10.1136/svn-2016-000042
Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial
https://doi.org/10.1161/strokeaha.121.037298
Hemoglobin and Perihematomal Edema After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial
https://doi.org/10.1007/s12028-025-02284-3
Predicting long-term outcomes in acute intracerebral haemorrhage using delayed prognostication scores
https://doi.org/10.1136/svn-2020-000656
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U01 NS074425)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P500PM_221974)
Freiwillige Akademische Gesellschaft
University of Basel
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 22 April 2025
First Online: 21 May 2025
Declarations
:
: Dr. Selim receives grant funding/support from the National Institutes of Health, National Institute of Neurological Disorders and Stroke, and National Institute on Aging (U01NS102289; UF1NS120871; UG3NS128397); serves as an advisory board member/consultant for MedRhythms, Inc., AegisCN, LLC, and Alnylam Pharmaceuticals; receives royalties from UpToDate, Inc. and Oxford University Press; and holds equity at NeuGel Therapeutics, Inc. The remaining authors report no conflicts of interest.
: Institutional review board approval was obtained for the parent study of this analysis, the i-DEF trial.
